Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. Assess long-term safety of oral apremilast in psoriasis patients. Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluati...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology Jg. 77; H. 2; S. 310 - 317.e1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Elsevier Inc
01.08.2017
Elsevier |
| Schlagworte: | |
| ISSN: | 0190-9622, 1097-6787, 1097-6787 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.
Assess long-term safety of oral apremilast in psoriasis patients.
Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2.
The 0 to ≥156–week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902.2 patient-years). During 0 to ≤52 weeks, the adverse events (AEs) that occurred in ≥5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. From 0 to ≥156 weeks, no new AEs (affecting ≥5% of the population) were reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term exposure. During the 0 to ≥156–week period, the rates of major cardiac events (exposure-adjusted incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with the rates found during the 0 to ≤52–week period. No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported.
This study had a high dropout rate (21% of patients ongoing >156 weeks); most were unrelated to safety concerns.
Apremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks. |
|---|---|
| AbstractList | Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.
Assess long-term safety of oral apremilast in psoriasis patients.
Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2.
The 0 to ≥156-week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902.2 patient-years). During 0 to ≤52 weeks, the adverse events (AEs) that occurred in ≥5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. From 0 to ≥156 weeks, no new AEs (affecting ≥5% of the population) were reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term exposure. During the 0 to ≥156-week period, the rates of major cardiac events (exposure-adjusted incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with the rates found during the 0 to ≤52-week period. No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported.
This study had a high dropout rate (21% of patients ongoing >156 weeks); most were unrelated to safety concerns.
Apremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks. Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term safety of oral apremilast in psoriasis patients. Methods Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2. Results The 0 to ≥156–week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902.2 patient-years). During 0 to ≤52 weeks, the adverse events (AEs) that occurred in ≥5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. From 0 to ≥156 weeks, no new AEs (affecting ≥5% of the population) were reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term exposure. During the 0 to ≥156–week period, the rates of major cardiac events (exposure-adjusted incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with the rates found during the 0 to ≤52–week period. No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported. Limitations This study had a high dropout rate (21% of patients ongoing >156 weeks); most were unrelated to safety concerns. Conclusions Apremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks. Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.BACKGROUNDRandomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.Assess long-term safety of oral apremilast in psoriasis patients.OBJECTIVEAssess long-term safety of oral apremilast in psoriasis patients.Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2.METHODSSafety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2.The 0 to ≥156-week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902.2 patient-years). During 0 to ≤52 weeks, the adverse events (AEs) that occurred in ≥5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. From 0 to ≥156 weeks, no new AEs (affecting ≥5% of the population) were reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term exposure. During the 0 to ≥156-week period, the rates of major cardiac events (exposure-adjusted incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with the rates found during the 0 to ≤52-week period. No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported.RESULTSThe 0 to ≥156-week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902.2 patient-years). During 0 to ≤52 weeks, the adverse events (AEs) that occurred in ≥5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. From 0 to ≥156 weeks, no new AEs (affecting ≥5% of the population) were reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term exposure. During the 0 to ≥156-week period, the rates of major cardiac events (exposure-adjusted incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with the rates found during the 0 to ≤52-week period. No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported.This study had a high dropout rate (21% of patients ongoing >156 weeks); most were unrelated to safety concerns.LIMITATIONSThis study had a high dropout rate (21% of patients ongoing >156 weeks); most were unrelated to safety concerns.Apremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks.CONCLUSIONSApremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks. Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.Objective: Assess long-term safety of oral apremilast in psoriasis patients.Methods: Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2.Results: The 0 to ≥156–week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902.2 patient-years). During 0 to ≤52 weeks, the adverse events (AEs) that occurred in ≥5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. From 0 to ≥156 weeks, no new AEs (affecting ≥5% of the population) were reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term exposure. During the 0 to ≥156–week period, the rates of major cardiac events (exposure-adjusted incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with the rates found during the 0 to ≤52–week period. No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported.Limitations: This study had a high dropout rate (21% of patients ongoing >156 weeks); most were unrelated to safety concerns.Conclusions: Apremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks. |
| Author | Joly, Pascal Goncalves, Joana Shah, Kamal Chen, Rongdean Cather, Jennifer C. Thaçi, Diamant Day, Robert M. Crowley, Jeffrey Peris, Ketty Ferrándiz, Carlos Papp, Kim A. |
| Author_xml | – sequence: 1 givenname: Jeffrey surname: Crowley fullname: Crowley, Jeffrey email: Crowley415@aol.com organization: Bakersfield Dermatology, Bakersfield, California – sequence: 2 givenname: Diamant surname: Thaçi fullname: Thaçi, Diamant organization: Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, Germany – sequence: 3 givenname: Pascal surname: Joly fullname: Joly, Pascal organization: Department of Dermatology, Hôpital Charles Nicolle, Université de Rouen, Rouen, France – sequence: 4 givenname: Ketty surname: Peris fullname: Peris, Ketty organization: Catholic University of Rome, Rome, Italy – sequence: 5 givenname: Kim A. surname: Papp fullname: Papp, Kim A. organization: Probity Medical Research, Waterloo, Ontario, Canada – sequence: 6 givenname: Joana surname: Goncalves fullname: Goncalves, Joana organization: Celgene Corporation, Summit, New Jersy – sequence: 7 givenname: Robert M. surname: Day fullname: Day, Robert M. organization: Celgene Corporation, Summit, New Jersy – sequence: 8 givenname: Rongdean surname: Chen fullname: Chen, Rongdean organization: Celgene Corporation, Summit, New Jersy – sequence: 9 givenname: Kamal surname: Shah fullname: Shah, Kamal organization: Celgene Corporation, Summit, New Jersy – sequence: 10 givenname: Carlos surname: Ferrándiz fullname: Ferrándiz, Carlos organization: Hospital Universitario Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain – sequence: 11 givenname: Jennifer C. surname: Cather fullname: Cather, Jennifer C. organization: Modern Research Associates, Dallas, Texas |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28416342$$D View this record in MEDLINE/PubMed https://hal.science/hal-02467951$$DView record in HAL |
| BookMark | eNqFkt9qFDEUxgep2G31BbyQXLbQWU8ys_OniFDKaoUVhdbrkEnOuNlmJmOSbVnfwLfwxifwDXwUn8SM2yoUrFcJH9_vSzjf2Ut2ettjkjylMKVAi-er6UoINWVAyynQKczYg2RCoS7ToqzKnWQCtIa0LhjbTfa8XwFAnWflo2SXVTktspxNku8L239MA7qOeNFi2BDRKxKsQScabXQUbEvE4LDTRvhAdE8GETT2wZNrHZZk8NZp4bU_Ju9t5NTfIGE2USetdeTnl290Vvz4eo14GRVnO8LIsBQeSXZEXHzUdvozqiMibR-cNWNQiMHGk4P5-cV8_pbQ339jh4-Th23U8cnNuZ98eDW_OD1LF-9evzk9WaRylkNIZQugMsFyqQTL2rYt4h1p09ZSsaoRtZC1zCRTTVZWahahpsyhBiiLFhFn2X5yuM1dCsMHpzvhNtwKzc9OFnzUgOVFWc_oFY3eg613cPbTGn3gnfYSjRE92rXntKrqrCpyKKL12Y113XSo_iTflhIN1dYgnfXeYculDnHm42CENpwCH_vnKz72z8f-OVAe-48ou4Pept8LvdhCGId5pdFxL2PBEpV2KANXVt-Pv7yDS6N7LYW5xA36lV27uAlxBNwzDvx83MpxKWmZAc2LOgYc_zvgf6__AoVz878 |
| CitedBy_id | crossref_primary_10_1080_00325481_2019_1575613 crossref_primary_10_1016_j_jid_2018_10_043 crossref_primary_10_1080_14740338_2020_1728253 crossref_primary_10_1111_dth_12923 crossref_primary_10_1111_jdv_16926 crossref_primary_10_1136_annrheumdis_2017_212629 crossref_primary_10_1177_1759720X20975915 crossref_primary_10_1111_bjd_19537 crossref_primary_10_1080_2331205X_2018_1495593 crossref_primary_10_1111_bjd_18047 crossref_primary_10_1055_a_1294_1580 crossref_primary_10_1111_bjd_20083 crossref_primary_10_1111_ijd_15205 crossref_primary_10_1016_j_ejca_2019_01_010 crossref_primary_10_1111_ijd_14598 crossref_primary_10_1111_jdv_16231 crossref_primary_10_1016_j_reumae_2017_08_002 crossref_primary_10_1001_jamadermatol_2023_5891 crossref_primary_10_1016_j_jaad_2020_06_051 crossref_primary_10_1007_s40261_020_00905_7 crossref_primary_10_1016_j_adengl_2020_01_009 crossref_primary_10_1080_1744666X_2020_1754194 crossref_primary_10_1016_j_coph_2022_102292 crossref_primary_10_1080_14740338_2020_1817379 crossref_primary_10_1111_1346_8138_15104 crossref_primary_10_1016_j_ad_2020_08_007 crossref_primary_10_1016_j_jdcr_2017_06_017 crossref_primary_10_1016_j_annder_2024_103251 crossref_primary_10_1016_j_jaad_2020_12_073 crossref_primary_10_1111_dth_15179 crossref_primary_10_2147_CCID_S266036 crossref_primary_10_1016_j_jaad_2019_03_017 crossref_primary_10_1111_jdv_20287 crossref_primary_10_1016_j_jaad_2018_06_027 crossref_primary_10_2217_imt_2019_0085 crossref_primary_10_1007_s40257_017_0302_0 crossref_primary_10_1111_ajd_14364 crossref_primary_10_2147_PHMT_S389108 crossref_primary_10_1007_s13555_020_00409_4 crossref_primary_10_1183_16000617_0206_2022 crossref_primary_10_25251_skin_3_2_39 crossref_primary_10_3390_biomedicines10061303 crossref_primary_10_1007_s11030_025_11159_w crossref_primary_10_1016_j_adengl_2020_05_003 crossref_primary_10_1186_s13063_021_05428_w crossref_primary_10_1016_j_autrev_2018_12_009 crossref_primary_10_1111_1346_8138_15831 crossref_primary_10_1111_1346_8138_16766 crossref_primary_10_1111_dth_13687 crossref_primary_10_3390_life14030395 crossref_primary_10_1016_j_ad_2023_05_022 crossref_primary_10_1111_dth_13448 crossref_primary_10_1080_14656566_2022_2060739 crossref_primary_10_1111_ajd_14134 crossref_primary_10_3389_fimmu_2020_626792 crossref_primary_10_1080_09546634_2020_1809623 crossref_primary_10_1136_gpsych_2019_100181 crossref_primary_10_1007_s12325_024_02873_2 crossref_primary_10_1080_14656566_2017_1409205 crossref_primary_10_4103_ijd_ijd_166_24 crossref_primary_10_1111_ddg_14507_g crossref_primary_10_1002_cia2_12049 crossref_primary_10_1016_j_jaad_2018_11_058 crossref_primary_10_1007_s13555_023_00933_z crossref_primary_10_1016_j_ad_2019_07_005 crossref_primary_10_1111_jdv_16683 crossref_primary_10_1111_jdv_16684 crossref_primary_10_1016_j_jaad_2019_08_019 crossref_primary_10_1007_s00105_019_4396_6 crossref_primary_10_1016_j_jaad_2020_03_043 crossref_primary_10_3390_ijms21197041 crossref_primary_10_1016_j_annder_2018_03_001 crossref_primary_10_1080_1744666X_2021_1919511 crossref_primary_10_1007_s40259_022_00569_z crossref_primary_10_3390_biomedicines10112879 crossref_primary_10_1016_j_adengl_2020_12_016 crossref_primary_10_36290_far_2025_035 crossref_primary_10_1111_bcp_15581 crossref_primary_10_3390_pharmaceutics17010091 crossref_primary_10_1093_ofid_ofz246 crossref_primary_10_1007_s40257_022_00703_1 crossref_primary_10_1007_s40266_020_00781_y crossref_primary_10_1016_j_berh_2018_08_003 crossref_primary_10_1111_ajd_13864 crossref_primary_10_1016_S0151_9638_18_30367_3 crossref_primary_10_36290_der_2018_016 crossref_primary_10_1016_j_jaad_2022_05_063 crossref_primary_10_1080_09546634_2019_1589641 crossref_primary_10_1016_j_cgh_2019_12_032 crossref_primary_10_1080_09546634_2018_1530439 crossref_primary_10_1007_s40257_023_00808_1 crossref_primary_10_1177_1759720X20930116 crossref_primary_10_2147_CCID_S320098 crossref_primary_10_1177_1203475420928382 crossref_primary_10_2147_PTT_S320810 crossref_primary_10_1111_dth_15258 crossref_primary_10_1111_jdv_20003 crossref_primary_10_1684_ejd_2017_3187 crossref_primary_10_1016_j_ad_2024_10_025 crossref_primary_10_3389_fmed_2020_543944 crossref_primary_10_1016_j_jaad_2023_10_020 crossref_primary_10_3390_ijms18102211 crossref_primary_10_1016_j_bioorg_2025_108511 crossref_primary_10_1080_1744666X_2022_2106969 crossref_primary_10_1111_ddg_14507 crossref_primary_10_1016_j_det_2024_02_013 crossref_primary_10_1016_j_annder_2019_04_016 crossref_primary_10_1111_1346_8138_16182 crossref_primary_10_1007_s00105_018_4156_z crossref_primary_10_1111_dth_15306 crossref_primary_10_1111_jdv_17749 crossref_primary_10_1111_jdv_19925 crossref_primary_10_23203_JKSP_2024_21_2_50 crossref_primary_10_1007_s40257_023_00783_7 crossref_primary_10_1016_j_ad_2020_05_008 crossref_primary_10_1111_dth_13809 crossref_primary_10_1080_14656566_2017_1378343 crossref_primary_10_1111_bjd_18233 crossref_primary_10_1111_bjd_20430 crossref_primary_10_1111_bjd_18519 |
| Cites_doi | 10.1016/j.jaad.2015.09.001 10.2215/CJN.08570814 10.1016/S0028-3908(98)00190-7 10.1001/jamadermatol.2015.3605 10.1038/jid.2013.508 10.1177/247553031420a00404 10.1016/j.amepre.2014.02.012 10.1111/bjd.14164 10.1111/j.1365-2133.2012.10830.x 10.1016/S0016-5085(76)80353-8 10.1111/bjd.14068 10.1001/jamadermatol.2015.0718 10.1111/ajt.13181 10.1016/j.jchemneu.2010.03.004 10.1016/j.jaad.2015.03.049 10.1016/j.jaad.2013.11.013 10.1136/annrheumdis-2015-207963 10.1007/s40259-015-0144-3 10.1165/rcmb.2013-0228OC 10.1001/archdermatol.2011.309 10.2340/00015555-2360 10.1038/jid.2012.339 10.1016/j.jaad.2016.02.1164 10.3899/jrheum.140647 10.1016/j.cellsig.2014.05.014 |
| ContentType | Journal Article |
| Copyright | 2017 American Academy of Dermatology, Inc. American Academy of Dermatology, Inc. Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. licence_http://creativecommons.org/publicdomain/zero |
| Copyright_xml | – notice: 2017 American Academy of Dermatology, Inc. – notice: American Academy of Dermatology, Inc. – notice: Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. – notice: licence_http://creativecommons.org/publicdomain/zero |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES |
| DOI | 10.1016/j.jaad.2017.01.052 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-6787 |
| EndPage | 317.e1 |
| ExternalDocumentID | oai:HAL:hal-02467951v1 28416342 10_1016_j_jaad_2017_01_052 S0190962217301469 1_s2_0_S0190962217301469 |
| Genre | Randomized Controlled Trial Clinical Trial, Phase III Journal Article |
| GroupedDBID | --- --K --M -RU .1- .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8F7 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HX~ HZ~ IHE J1W J5H KOM LZ2 M27 M41 MO0 N9A O-L O9- OAUVE OB. OBH OHH OM~ OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SJN SPCBC SSH SSZ T5K TEORI UHS UNMZH UV1 WOW WUQ Y6R YFH Z5R ZCG ZGI ZY1 ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW PKN RIG 6I. AAFTH AAIAV ABLVK ABYKQ AJBFU LCYCR 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES |
| ID | FETCH-LOGICAL-c540t-cf00d3a24cda23fff6a24e1bf9cd28ba9ac9c3c2db378d5c54b74090076feee53 |
| ISICitedReferencesCount | 138 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000405298300030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0190-9622 1097-6787 |
| IngestDate | Tue Nov 18 06:21:04 EST 2025 Thu Oct 02 09:51:04 EDT 2025 Wed Feb 19 02:13:40 EST 2025 Sat Nov 29 07:28:32 EST 2025 Tue Nov 18 22:09:22 EST 2025 Fri Feb 23 02:24:42 EST 2024 Sun Feb 23 10:19:04 EST 2025 Tue Oct 14 19:33:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | clinical trial ESTEEM GI AE EAIR psoriasis safety PDE4 phosphodiesterase 4 inhibitor psoriatic arthritis apremilast TB Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis tuberculosis adverse event gastrointestinal exposure-adjusted incidence rate phosphodiesterase 4 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. licence_http://creativecommons.org/publicdomain/zero/: http://creativecommons.org/publicdomain/zero |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c540t-cf00d3a24cda23fff6a24e1bf9cd28ba9ac9c3c2db378d5c54b74090076feee53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://hal.science/hal-02467951 |
| PMID | 28416342 |
| PQID | 1889386406 |
| PQPubID | 23479 |
| ParticipantIDs | hal_primary_oai_HAL_hal_02467951v1 proquest_miscellaneous_1889386406 pubmed_primary_28416342 crossref_citationtrail_10_1016_j_jaad_2017_01_052 crossref_primary_10_1016_j_jaad_2017_01_052 elsevier_sciencedirect_doi_10_1016_j_jaad_2017_01_052 elsevier_clinicalkeyesjournals_1_s2_0_S0190962217301469 elsevier_clinicalkey_doi_10_1016_j_jaad_2017_01_052 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-08-01 |
| PublicationDateYYYYMMDD | 2017-08-01 |
| PublicationDate_xml | – month: 08 year: 2017 text: 2017-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of the American Academy of Dermatology |
| PublicationTitleAlternate | J Am Acad Dermatol |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Rachakonda, Schupp, Armstrong (bib2) 2014; 70 Parisi, Symmons, Griffiths, Ashcroft (bib3) 2013; 133 Rich, Gooderham, Bachelez (bib11) 2016; 74 Cameron, Baillie (bib17) 2012 Helmick, Lee-Han, Hirsch, Baird, Bartlett (bib1) 2014; 47 Edwards, Blanco, Crowley (bib12) 2016; 75 Gooderham, Papp (bib24) 2015; 29 Dowlatshahi, Wakkee, Arends, Nijsten (bib25) 2014; 134 Wiseman (bib30) 2016; 11 (bib23) December 2015 Paul, Cather, Gooderham (bib10) 2015; 173 Kimball, Schenfeld, Accortt, Anthony, Rothman, Pariser (bib28) 2015; 173 Schaarschmidt, Schmieder, Umar (bib4) 2011; 147 Schafer, Parton, Capone (bib8) 2014; 26 Gottlieb, Kalb, Langley (bib26) 2014; 13 Kavanaugh, Mease, Gomez-Reino (bib13) 2015; 42 Wald, Back, Bayless (bib19) 1976; 71 Robichaud, Tattersall, Choudhury, Rodger (bib21) 1999; 38 Sobell, Foley, Toth (bib15) 2016; 96 Mori, Perez-Torres, De Caro (bib20) 2010; 40 Vincenti, Silva, Busque (bib29) 2015; 15 Abraham BP, Shah K, Levi E, Sellin JH. Apremilast for the treatment of psoriasis and psoriatic arthritis: management of gastrointestinal adverse effects [poster]. Presented at: Annual Maui Derm for Dermatologists; January 25-29, 2016; Maui, HI. Lebwohl, Kavanaugh, Armstrong, Van Voorhees, Kalb (bib5) 2014; 20 Emer, Frankel, Zeichner (bib6) 2010; 3 Cohen, Martires, Ho (bib7) 2016; 152 Kalb, Fiorentino, Lebwohl (bib27) 2015; 151 Papp, Reich, Leonardi (bib9) 2015; 73 Lambert, Raju, Tang (bib18) 2014; 50 Bissonnette, Pariser, Wasel (bib14) 2016; 75 Lomas, Leonardi-Bee, Bath-Hextall (bib16) 2012; 166 Gooderham (10.1016/j.jaad.2017.01.052_bib24) 2015; 29 Kalb (10.1016/j.jaad.2017.01.052_bib27) 2015; 151 Lambert (10.1016/j.jaad.2017.01.052_bib18) 2014; 50 Dowlatshahi (10.1016/j.jaad.2017.01.052_bib25) 2014; 134 Bissonnette (10.1016/j.jaad.2017.01.052_bib14) 2016; 75 Wald (10.1016/j.jaad.2017.01.052_bib19) 1976; 71 10.1016/j.jaad.2017.01.052_bib22 Vincenti (10.1016/j.jaad.2017.01.052_bib29) 2015; 15 Wiseman (10.1016/j.jaad.2017.01.052_bib30) 2016; 11 Rachakonda (10.1016/j.jaad.2017.01.052_bib2) 2014; 70 Schaarschmidt (10.1016/j.jaad.2017.01.052_bib4) 2011; 147 Schafer (10.1016/j.jaad.2017.01.052_bib8) 2014; 26 Kavanaugh (10.1016/j.jaad.2017.01.052_bib13) 2015; 42 Edwards (10.1016/j.jaad.2017.01.052_bib12) 2016; 75 Lebwohl (10.1016/j.jaad.2017.01.052_bib5) 2014; 20 Robichaud (10.1016/j.jaad.2017.01.052_bib21) 1999; 38 Paul (10.1016/j.jaad.2017.01.052_bib10) 2015; 173 Lomas (10.1016/j.jaad.2017.01.052_bib16) 2012; 166 Kimball (10.1016/j.jaad.2017.01.052_bib28) 2015; 173 Cameron (10.1016/j.jaad.2017.01.052_bib17) 2012 Rich (10.1016/j.jaad.2017.01.052_bib11) 2016; 74 Papp (10.1016/j.jaad.2017.01.052_bib9) 2015; 73 Sobell (10.1016/j.jaad.2017.01.052_bib15) 2016; 96 Parisi (10.1016/j.jaad.2017.01.052_bib3) 2013; 133 Cohen (10.1016/j.jaad.2017.01.052_bib7) 2016; 152 Mori (10.1016/j.jaad.2017.01.052_bib20) 2010; 40 (10.1016/j.jaad.2017.01.052_bib23) 2015 Helmick (10.1016/j.jaad.2017.01.052_bib1) 2014; 47 Gottlieb (10.1016/j.jaad.2017.01.052_bib26) 2014; 13 Emer (10.1016/j.jaad.2017.01.052_bib6) 2010; 3 |
| References_xml | – volume: 20 start-page: 124 year: 2014 end-page: 131 ident: bib5 article-title: Patient perspectives on psoriasis management: U.S. results of the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey publication-title: Psoriasis Forum – volume: 74 start-page: 134 year: 2016 end-page: 142 ident: bib11 article-title: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2) publication-title: J Am Acad Dermatol – volume: 70 start-page: 512 year: 2014 end-page: 516 ident: bib2 article-title: Psoriasis prevalence among adults in the United States publication-title: J Am Acad Dermatol – volume: 166 start-page: 1069 year: 2012 end-page: 1080 ident: bib16 article-title: A systematic review of worldwide incidence of nonmelanoma skin cancer publication-title: Br J Dermatol – volume: 26 start-page: 2016 year: 2014 end-page: 2029 ident: bib8 article-title: Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity publication-title: Cell Signal – volume: 15 start-page: 1644 year: 2015 end-page: 1653 ident: bib29 article-title: Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients publication-title: Am J Transplant – volume: 3 start-page: 20 year: 2010 end-page: 26 ident: bib6 article-title: A practical approach to monitoring patients on biological agents for the treatment of psoriasis publication-title: J Clin Aesthet Dermatol – volume: 147 start-page: 1285 year: 2011 end-page: 1294 ident: bib4 article-title: Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes publication-title: Arch Dermatol – volume: 151 start-page: 961 year: 2015 end-page: 969 ident: bib27 article-title: Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) publication-title: JAMA Dermatol – volume: 47 start-page: 37 year: 2014 end-page: 45 ident: bib1 article-title: Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination surveys publication-title: Am J Prev Med – volume: 38 start-page: 289 year: 1999 end-page: 297 ident: bib21 article-title: Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret publication-title: Neuropharmacology – volume: 75 start-page: 1065 year: 2016 end-page: 1073 ident: bib12 article-title: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) publication-title: Ann Rheum Dis – volume: 152 start-page: 73 year: 2016 end-page: 79 ident: bib7 article-title: Psoriasis and the risk of depression in the US population: National Health and Nutrition Examination survey 2009-2012 publication-title: JAMA Dermatol – volume: 40 start-page: 36 year: 2010 end-page: 42 ident: bib20 article-title: The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D publication-title: J Chem Neuroanat – volume: 13 start-page: 1441 year: 2014 end-page: 1448 ident: bib26 article-title: Safety observations in 12,095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies publication-title: J Drugs Dermatol – start-page: 1 year: 2012 end-page: 35 ident: bib17 article-title: cAMP-specific phosphodiesterases: modulation, inhibition, and activation publication-title: Therapeutic targets: modulation, inhibition, and activation – volume: 50 start-page: 549 year: 2014 end-page: 558 ident: bib18 article-title: Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis publication-title: Am J Respir Cell Mol Biol – volume: 134 start-page: 1542 year: 2014 end-page: 1551 ident: bib25 article-title: The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis publication-title: J Invest Dermatol – volume: 11 start-page: 332 year: 2016 end-page: 343 ident: bib30 article-title: Immunosuppressive medications publication-title: Clin J Am Soc Nephrol – volume: 133 start-page: 377 year: 2013 end-page: 385 ident: bib3 article-title: Global epidemiology of psoriasis: a systematic review of incidence and prevalence publication-title: J Invest Dermatol – volume: 75 start-page: 99 year: 2016 end-page: 105 ident: bib14 article-title: Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis publication-title: J Am Acad Dermatol – volume: 71 start-page: 738 year: 1976 end-page: 742 ident: bib19 article-title: Effect of caffeine on the human small intestine publication-title: Gastroenterology – volume: 42 start-page: 479 year: 2015 end-page: 488 ident: bib13 article-title: Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis publication-title: J Rheumatol – reference: Abraham BP, Shah K, Levi E, Sellin JH. Apremilast for the treatment of psoriasis and psoriatic arthritis: management of gastrointestinal adverse effects [poster]. Presented at: Annual Maui Derm for Dermatologists; January 25-29, 2016; Maui, HI. – volume: 173 start-page: 1387 year: 2015 end-page: 1399 ident: bib10 article-title: Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2) publication-title: Br J Dermatol – volume: 29 start-page: 327 year: 2015 end-page: 339 ident: bib24 article-title: Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast publication-title: Biodrugs – volume: 96 start-page: 514 year: 2016 end-page: 520 ident: bib15 article-title: Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis publication-title: Acta Derm Venereol – year: December 2015 ident: bib23 publication-title: Otezla [package insert] – volume: 73 start-page: 37 year: 2015 end-page: 49 ident: bib9 article-title: Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]) publication-title: J Am Acad Dermatol – volume: 173 start-page: 1183 year: 2015 end-page: 1190 ident: bib28 article-title: Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States publication-title: Br J Dermatol – volume: 74 start-page: 134 issue: 1 year: 2016 ident: 10.1016/j.jaad.2017.01.052_bib11 article-title: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2) publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2015.09.001 – volume: 11 start-page: 332 issue: 2 year: 2016 ident: 10.1016/j.jaad.2017.01.052_bib30 article-title: Immunosuppressive medications publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.08570814 – volume: 38 start-page: 289 issue: 2 year: 1999 ident: 10.1016/j.jaad.2017.01.052_bib21 article-title: Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret publication-title: Neuropharmacology doi: 10.1016/S0028-3908(98)00190-7 – volume: 152 start-page: 73 issue: 1 year: 2016 ident: 10.1016/j.jaad.2017.01.052_bib7 article-title: Psoriasis and the risk of depression in the US population: National Health and Nutrition Examination survey 2009-2012 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2015.3605 – volume: 134 start-page: 1542 issue: 6 year: 2014 ident: 10.1016/j.jaad.2017.01.052_bib25 article-title: The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis publication-title: J Invest Dermatol doi: 10.1038/jid.2013.508 – volume: 20 start-page: 124 issue: 4 year: 2014 ident: 10.1016/j.jaad.2017.01.052_bib5 article-title: Patient perspectives on psoriasis management: U.S. results of the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey publication-title: Psoriasis Forum doi: 10.1177/247553031420a00404 – year: 2015 ident: 10.1016/j.jaad.2017.01.052_bib23 – volume: 47 start-page: 37 issue: 1 year: 2014 ident: 10.1016/j.jaad.2017.01.052_bib1 article-title: Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination surveys publication-title: Am J Prev Med doi: 10.1016/j.amepre.2014.02.012 – volume: 3 start-page: 20 issue: 8 year: 2010 ident: 10.1016/j.jaad.2017.01.052_bib6 article-title: A practical approach to monitoring patients on biological agents for the treatment of psoriasis publication-title: J Clin Aesthet Dermatol – volume: 173 start-page: 1387 issue: 6 year: 2015 ident: 10.1016/j.jaad.2017.01.052_bib10 article-title: Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2) publication-title: Br J Dermatol doi: 10.1111/bjd.14164 – volume: 166 start-page: 1069 issue: 5 year: 2012 ident: 10.1016/j.jaad.2017.01.052_bib16 article-title: A systematic review of worldwide incidence of nonmelanoma skin cancer publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2012.10830.x – volume: 71 start-page: 738 issue: 5 year: 1976 ident: 10.1016/j.jaad.2017.01.052_bib19 article-title: Effect of caffeine on the human small intestine publication-title: Gastroenterology doi: 10.1016/S0016-5085(76)80353-8 – volume: 173 start-page: 1183 issue: 5 year: 2015 ident: 10.1016/j.jaad.2017.01.052_bib28 article-title: Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States publication-title: Br J Dermatol doi: 10.1111/bjd.14068 – volume: 151 start-page: 961 issue: 9 year: 2015 ident: 10.1016/j.jaad.2017.01.052_bib27 article-title: Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2015.0718 – volume: 15 start-page: 1644 issue: 6 year: 2015 ident: 10.1016/j.jaad.2017.01.052_bib29 article-title: Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients publication-title: Am J Transplant doi: 10.1111/ajt.13181 – volume: 40 start-page: 36 issue: 1 year: 2010 ident: 10.1016/j.jaad.2017.01.052_bib20 article-title: The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D publication-title: J Chem Neuroanat doi: 10.1016/j.jchemneu.2010.03.004 – volume: 73 start-page: 37 issue: 1 year: 2015 ident: 10.1016/j.jaad.2017.01.052_bib9 article-title: Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]) publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2015.03.049 – volume: 13 start-page: 1441 issue: 12 year: 2014 ident: 10.1016/j.jaad.2017.01.052_bib26 article-title: Safety observations in 12,095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies publication-title: J Drugs Dermatol – start-page: 1 year: 2012 ident: 10.1016/j.jaad.2017.01.052_bib17 article-title: cAMP-specific phosphodiesterases: modulation, inhibition, and activation – volume: 70 start-page: 512 issue: 3 year: 2014 ident: 10.1016/j.jaad.2017.01.052_bib2 article-title: Psoriasis prevalence among adults in the United States publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2013.11.013 – volume: 75 start-page: 1065 issue: 6 year: 2016 ident: 10.1016/j.jaad.2017.01.052_bib12 article-title: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-207963 – volume: 29 start-page: 327 issue: 5 year: 2015 ident: 10.1016/j.jaad.2017.01.052_bib24 article-title: Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast publication-title: Biodrugs doi: 10.1007/s40259-015-0144-3 – volume: 50 start-page: 549 issue: 3 year: 2014 ident: 10.1016/j.jaad.2017.01.052_bib18 article-title: Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis publication-title: Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2013-0228OC – ident: 10.1016/j.jaad.2017.01.052_bib22 – volume: 147 start-page: 1285 issue: 11 year: 2011 ident: 10.1016/j.jaad.2017.01.052_bib4 article-title: Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes publication-title: Arch Dermatol doi: 10.1001/archdermatol.2011.309 – volume: 96 start-page: 514 issue: 4 year: 2016 ident: 10.1016/j.jaad.2017.01.052_bib15 article-title: Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis publication-title: Acta Derm Venereol doi: 10.2340/00015555-2360 – volume: 133 start-page: 377 issue: 2 year: 2013 ident: 10.1016/j.jaad.2017.01.052_bib3 article-title: Global epidemiology of psoriasis: a systematic review of incidence and prevalence publication-title: J Invest Dermatol doi: 10.1038/jid.2012.339 – volume: 75 start-page: 99 year: 2016 ident: 10.1016/j.jaad.2017.01.052_bib14 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2016.02.1164 – volume: 42 start-page: 479 issue: 3 year: 2015 ident: 10.1016/j.jaad.2017.01.052_bib13 article-title: Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis publication-title: J Rheumatol doi: 10.3899/jrheum.140647 – volume: 26 start-page: 2016 issue: 9 year: 2014 ident: 10.1016/j.jaad.2017.01.052_bib8 article-title: Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity publication-title: Cell Signal doi: 10.1016/j.cellsig.2014.05.014 |
| SSID | ssj0009437 |
| Score | 2.5857394 |
| Snippet | Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.
Assess long-term... Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.... Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic... Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 310 |
| SubjectTerms | Adult Anti-Inflammatory Agents, Non-Steroidal - adverse effects apremilast Cardiovascular Diseases - epidemiology clinical trial Depression - epidemiology Dermatology Diarrhea - chemically induced ESTEEM Female Headache - chemically induced Human health and pathology Humans Immunology Immunotherapy Incidence Life Sciences Male Middle Aged Nasopharyngitis - chemically induced Nausea - chemically induced Neoplasms - epidemiology phosphodiesterase 4 inhibitor psoriasis Psoriasis - drug therapy psoriatic arthritis Respiratory Tract Infections - chemically induced Rhumatology and musculoskeletal system safety Santé publique et épidémiologie Suicide, Attempted - statistics & numerical data Tension-Type Headache - chemically induced Thalidomide - adverse effects Thalidomide - analogs & derivatives Time Factors |
| Title | Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0190962217301469 https://www.clinicalkey.es/playcontent/1-s2.0-S0190962217301469 https://dx.doi.org/10.1016/j.jaad.2017.01.052 https://www.ncbi.nlm.nih.gov/pubmed/28416342 https://www.proquest.com/docview/1889386406 https://hal.science/hal-02467951 |
| Volume | 77 |
| WOSCitedRecordID | wos000405298300030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1097-6787 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009437 issn: 0190-9622 databaseCode: AIEXJ dateStart: 20170401 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLbWDXEF4p_yMxnEJFDXKbHTJuauGkVjbNOkDal3kZs4LKNLqqYbgzfgLbjhCXgDHoUn4RzbSbpffiRuqjSKHSfni8_x8XfOIeRZx4kDXySyzbF0gAc2OMyDAj933GOTTDhDRxeb8Le2gsFAbM81rpWxMEcjP8uC42Mx_q-ihnMgbAyd_QtxV53CCTgGocMviB1-_0jwG3n2vo0TbquQCRIyNUcyH6mJScmtt9TleKIOUrCcdYUAm1zVRrqNixyGWaSaLLedQ8u47sqmMEFyouZJiKUe2CrdpVW21HM-KvWhMBErrDXeAwXZ4ihD0IdxfpB-No5Vy47HbnXNEO337e_s9vubLVePlpX-ibNW80wkTGbJ_fqBXqGGmZ7YI1idoLvw00y8Ws2CkZog4Jso-1QeyJr-s56b4tvbsojkqFYdE5ON4a2amswppa8E9G_J1LMOvDKI5wTHVEfTiy47oRRsbZl0Zm1uZnhuWbjK_vNXlHuuKjJekf2VfSkxIy1ciOlhTbreUym-d3AIOAIX51uvKxpkgfkdEcyThd6b_mC9TiPt8SoBADawYWCGsXj6TheZWo095PxetKDShtXuDXLdypb2DJJvkjmV3SJXNy3n4zb5XgGaGhRSgAidBTTNE1oDmqYZLQFNEdC0AvRLauBcd2TgTAHO9OeXbwDkH181iCmCmDKqQUz5Mq0hvExrAFMDYPrcwJe6emzsxR3y7nV_d3WtbUuNtCNYskzbUeI4MZfMi2LJeJIkXThW7jARUcyCoRQyEhGPWDzkfhB3oNHQ92BOc_xuopTq8LtkPsszdZ9QIQVDTef5THrMk0IpsOJ5ZygjlyeO2yRuKZUwsnn4sRzMKCwJl_shSjJESYaOG4Ikm6RVtRmbLDSXXs1LYYdlfDVYBCEg89JW_nmtVGHntiJ0w4KFTngGrU3SqVpau93Y47-941NAYvVAmOh-rbcR4jlYOXR9WPwdwet6UgI1BM2H25kyU_khDCeAtVbQhRVJk9wzCK76Ysim4B578E-v4iF675hnZo9HZH46OVSPyZXoaJoWk0XS8AfBov0yfwHhCjBo |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+safety+and+tolerability+of+apremilast+in+patients+with+psoriasis%3A+Pooled+safety+analysis+for+%E2%89%A5156%C2%A0weeks+from+2+phase+3%2C+randomized%2C+controlled+trials+%28ESTEEM+1+and+2%29&rft.jtitle=Journal+of+the+American+Academy+of+Dermatology&rft.au=Crowley%2C+Jeffrey&rft.au=Tha%C3%A7i%2C+Diamant&rft.au=Joly%2C+Pascal&rft.au=Peris%2C+Ketty&rft.date=2017-08-01&rft.pub=Elsevier+Inc&rft.issn=0190-9622&rft.volume=77&rft.issue=2&rft.spage=310&rft.epage=317.e1&rft_id=info:doi/10.1016%2Fj.jaad.2017.01.052&rft.externalDocID=S0190962217301469 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0190-9622&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0190-9622&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0190-9622&client=summon |